The Research Group Lewis Hargett Circle
Welcome,         Profile    Billing    Logout  
 0 Trials 
13 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gutierrez, Alexis
GMRx2_PCT, NCT04518306: Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension

Completed
3
295
Europe, US, RoW
Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo
George Medicines PTY Limited
Hypertension
09/23
10/23
GMRx2_ACT, NCT04518293: Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension

Completed
3
1385
Europe, US, RoW
Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg ., telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg
George Medicines PTY Limited
Hypertension
08/23
09/23
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06267560: Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD

Recruiting
3
400
US
TQJ230, pelacarsen, Placebo
Novartis Pharmaceuticals
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
03/27
03/27
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
V-Mono, NCT05763875: Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

Completed
3
350
Europe, US, RoW
Inclisiran, KJX839, Ezetimibe, Sandoz ezetimibe, Matching Placebo for Inclisiran, Placebo s.c., Matching Placebo for Ezetimibe, Placebo p.o.
Novartis Pharmaceuticals
Hypercholesterolemia
06/24
06/24
V-PLAQUE, NCT05360446: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Active, not recruiting
3
608
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Coronary Artery Disease
01/27
01/27
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17004
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

Terminated
2
136
Europe, Japan, US, RoW
Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan
Novartis Pharmaceuticals
Heart Failure
11/24
11/24
Petschonek, Leann
VICTORION-1 PREVENT, NCT05739383: A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

Active, not recruiting
3
14013
Europe, Canada, US, RoW
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml
Novartis Pharmaceuticals
Primary Prevention of Atherosclerotic Cardiovascular Disease
04/29
04/29
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

Terminated
2
136
Europe, Japan, US, RoW
Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan
Novartis Pharmaceuticals
Heart Failure
11/24
11/24
Pelletier, Robyn
NCT06142383: A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure

Terminated
2
136
Europe, Japan, US, RoW
Placebo, XXB750 Low dose, XXB750 Medium Dose, XXB750 High Dose, Sacubitril/valsartan
Novartis Pharmaceuticals
Heart Failure
11/24
11/24

Download Options